Search

Your search keyword '"N. Bakrin"' showing total 13 results
Start Over Author "N. Bakrin" Language french
13 results on '"N. Bakrin"'

1. [CHIP and ovarian cancer]

Author

F, Lécuru, N, Bakrin, J M, Classe, P E, Colombo, G, Ferron, G, Freyer, O, Glehen, S, Gouy, C, Huchon, F, Narducci, M, Pocard, C, Pomel, and R, Rouzier

Subjects
Ovarian Neoplasms, Humans, Female, Hyperthermia, Induced
Published
2019

2. [Part II drafted from the short text of the French guidelines entitled 'Initial management of patients with epithelial ovarian cancer' developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)]

Author

V, Lavoué, C, Huchon, C, Akladios, P, Alfonsi, N, Bakrin, M, Ballester, S, Bendifallah, P A, Bolze, F, Bonnet, C, Bourgin, N, Chabbert-Buffet, P, Collinet, B, Courbiere, T, De la Motte Rouge, M, Devouassoux-Shisheboran, C, Falandry, G, Ferron, L, Fournier, L, Gladieff, F, Golfier, S, Gouy, F, Guyon, E, Lambaudie, A, Leary, F, Lécuru, M A, Lefrère-Belda, E, Leblanc, A, Lemoine, F, Narducci, L, Ouldamer, P, Pautier, F, Planchamp, N, Pouget, I, Ray-Coquard, C, Rousset-Jablonski, C, Sénéchal-Davin, C, Touboul, I, Thomassin-Naggara, C, Uzan, B, You, and E, Daraï

Subjects
Ovarian Neoplasms, Age Factors, Fertility Preservation, Hyperthermia, Induced, Carcinoma, Ovarian Epithelial, Continuity of Patient Care, Chemotherapy, Adjuvant, Biomarkers, Tumor, Fallopian Tube Neoplasms, Humans, Female, France, Peritoneal Neoplasms, Societies, Medical
Abstract

Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A). For BRCA mutated patient, Olaparib is recommended (grade B).

Published
2018

3. [Part I drafted from the short text of the French Guidelines entitled 'Initial management of patients with epithelial ovarian cancer' developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)]

Author

V, Lavoué, C, Huchon, C, Akladios, P, Alfonsi, N, Bakrin, M, Ballester, S, Bendifallah, P A, Bolze, F, Bonnet, C, Bourgin, N, Chabbert-Buffet, P, Collinet, B, Courbiere, T, De la Motte Rouge, M, Devouassoux-Shisheboran, C, Falandry, G, Ferron, L, Fournier, L, Gladieff, F, Golfier, S, Gouy, F, Guyon, E, Lambaudie, A, Leary, F, Lécuru, M A, Lefrère-Belda, E, Leblanc, A, Lemoine, F, Narducci, L, Ouldamer, P, Pautier, F, Planchamp, N, Pouget, I, Ray-Coquard, C, Rousset-Jablonski, C, Sénéchal-Davin, C, Touboul, I, Thomassin-Naggara, C, Uzan, B, You, and E, Daraï

Subjects
Ovarian Neoplasms, Membrane Proteins, Proteins, Antineoplastic Agents, DNA, Neoplasm, Carcinoma, Ovarian Epithelial, Combined Modality Therapy, Perioperative Care, WAP Four-Disulfide Core Domain Protein 2, CA-125 Antigen, Biomarkers, Tumor, Fallopian Tube Neoplasms, Humans, Lymph Node Excision, Female, Laparoscopy, France, Neoplasm Metastasis, Algorithms, Peritoneal Neoplasms, Societies, Medical, Neoplasm Staging
Abstract

Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B).

Published
2018

4. [Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled 'Initial management of patients with epithelial ovarian cancer' developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa]

Author

N, Bakrin and L, Gladieff

Subjects
Ovarian Neoplasms, Paclitaxel, Hyperthermia, Induced, Carcinoma, Ovarian Epithelial, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols, Quality of Life, Fallopian Tube Neoplasms, Humans, Female, France, Cisplatin, Peritoneal Neoplasms, Societies, Medical
Abstract

Intraperitoneal drug delivery in first-line treatment of advanced ovarian cancer have been widely studied. After a complete primary surgery or with residual disease1cm, intraperitoneal chemotherapy significantly improves disease-free and overall survival (NP1), but with more local and systemic toxicities. Whenever this therapeutic option is under consideration, the ratio efficacy/toxicity must be carefully discussed. Intraperitoneal chemotherapy has to be considered after complete or optimal primary surgery in ovarian, tubal or primitive peritoneal carcinomatosis FIGO IIIC. This treatment must be performed by trained teams and after an assessment of the ratio efficacy/toxicity. In one randomized study, hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatinum at interval surgery demonstrated an improvement in recurrence free and overall survival compared to surgery alone, in patients initially not resectable and with residual tumor less than 1cm (complete or optimal surgery) (NP1). HIPEC has to be considered after a complete or optimal interval surgery (residu10mm) in patients with ovarian, tubal or primitive carcinomatosis FIGO IIIC, initially not resectable (Grade B).

Published
2018

5. [HIPEC and ovarian carcinoma: base judgment on evidence]

Author

N, Bakrin, O, Glehen, and F, Golfier

Subjects
Ovarian Neoplasms, Treatment Outcome, Organoplatinum Compounds, Carcinoma, Humans, Antineoplastic Agents, Female, Infusions, Parenteral, Hyperthermia, Induced, Randomized Controlled Trials as Topic
Published
2011

6. [Severe gestational hypertriglyceridemia: related complications and management]

Author

C, Huissoud, J-M, Robert, N, Bakrin, R-C, Rudigoz, and A, Levrat

Subjects
Adult, Hypertriglyceridemia, Pregnancy Complications, Pancreatitis, Pregnancy, Pregnancy Trimester, Second, Pregnancy Trimester, Third, Pregnancy Outcome, Humans, Female, Acute Kidney Injury, Fetal Death, Fetal Distress
Abstract

We present two cases of severe hypertriglyceridemia (HTG10g/l) in pregnancy. The first reports the case of a primigravida with mild HTG before conception. Triglycerides (TG) increased thereafter (20.9g/l) during pregnancy causing pancreatitis and in utero fetal death at 24 weeks' gestation (WG). The second deals with the de novo occurrence of a severe HTG (19g/l) diagnosed incidentally at 34 WG and complicated by acute renal failure. Severe HTG in pregnancy threatens maternal and fetal prognosis. We have summarized the curative and preventive management of gravidic HTG.

Published
2007

7. [CHIP and ovarian cancer].

Author

Lécuru F, Bakrin N, Classe JM, Colombo PE, Ferron G, Freyer G, Glehen O, Gouy S, Huchon C, Narducci F, Pocard M, Pomel C, and Rouzier R

Subjects
Female, Humans, Hyperthermia, Induced methods, Ovarian Neoplasms therapy
Published
2019
Full Text
View/download PDF

8. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].

Author

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, and Daraï E

Subjects
Antineoplastic Agents therapeutic use, Bevacizumab therapeutic use, Chemotherapy, Adjuvant, Female, France, Humans, Hyperthermia, Induced, Lymph Node Excision, Magnetic Resonance Imaging, Phthalazines therapeutic use, Piperazines therapeutic use, Societies, Medical, Ultrasonography, Carcinoma, Ovarian Epithelial diagnostic imaging, Carcinoma, Ovarian Epithelial drug therapy, Carcinoma, Ovarian Epithelial pathology, Carcinoma, Ovarian Epithelial surgery, Fallopian Tube Neoplasms diagnostic imaging, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms pathology, Fallopian Tube Neoplasms surgery, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms drug therapy, Ovarian Neoplasms pathology, Ovarian Neoplasms surgery, Peritoneal Neoplasms diagnostic imaging, Peritoneal Neoplasms drug therapy, Peritoneal Neoplasms pathology, Peritoneal Neoplasms surgery
Abstract

Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). In case of ovarian, Fallopian tube or primitive peritoneal cancer of FIGO III-IV stages, thoraco-abdomino-pelvic CT scan with injection (grade B) is recommended. Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A)., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)

Published
2019
Full Text
View/download PDF

9. [Part I drafted from the short text of the French Guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Diagnosis management, surgery, perioperative care, and pathological analysis)].

Author

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, and Daraï E

Subjects
Algorithms, Antineoplastic Agents therapeutic use, Biomarkers, Tumor analysis, CA-125 Antigen analysis, Carcinoma, Ovarian Epithelial diagnostic imaging, Carcinoma, Ovarian Epithelial pathology, Combined Modality Therapy, DNA, Neoplasm blood, Fallopian Tube Neoplasms pathology, Fallopian Tube Neoplasms therapy, Female, France, Humans, Laparoscopy, Lymph Node Excision, Membrane Proteins analysis, Neoplasm Metastasis therapy, Neoplasm Staging, Ovarian Neoplasms diagnostic imaging, Ovarian Neoplasms pathology, Perioperative Care, Peritoneal Neoplasms pathology, Peritoneal Neoplasms therapy, Proteins analysis, Societies, Medical, WAP Four-Disulfide Core Domain Protein 2, Carcinoma, Ovarian Epithelial therapy, Ovarian Neoplasms therapy
Abstract

Faced to an undetermined ovarian mass on ultrasound, an MRI is recommended and the ROMA score (combining CA125 and HE4) can be proposed (grade A). In case of suspected early stage ovarian or fallopian tube cancer, omentectomy (at least infracolonic), appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C) and pelvic and para-aortic lymphadenectomy are recommended (grade B) for all histological types, except for the expansive mucinous subtype where lymphadenectomy may be omitted (grade C). Minimally invasive surgery is recommended for early stage ovarian cancer, if there is no risk of tumor rupture (grade B). Laparoscopic exploration for multiple biopsies (grade A) and to evaluate carcinomatosis score (at least using the Fagotti score) (grade C) are recommended to estimate the possibility of a complete surgery (i.e. no macroscopic residue). Complete medial laparotomy surgery is recommended for advanced cancers (grade B). It is recommended in advanced cancers to perform para-aortic and pelvic lymphadenectomy in case of clinical or radiological suspicion of metastatic lymph node (grade B). In the absence of clinical or radiological lymphadenopathy and in case of complete peritoneal surgery during an initial surgery for advanced cancer, it is possible not to perform a lymphadenectomy because it does not modify the medical treatment and the overall survival (grade B). Primary surgery is recommended when no tumor residue is possible (grade B)., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)

Published
2019
Full Text
View/download PDF

10. [Part II drafted from the short text of the French guidelines entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. (Systemic and intraperitoneal treatment, elderly, fertility preservation, follow-up)].

Author

Lavoué V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lécuru F, Lefrère-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Sénéchal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, and Daraï E

Subjects
Age Factors, Biomarkers, Tumor analysis, Carcinoma, Ovarian Epithelial pathology, Chemotherapy, Adjuvant, Continuity of Patient Care, Fallopian Tube Neoplasms pathology, Fallopian Tube Neoplasms therapy, Female, Fertility Preservation, France, Humans, Hyperthermia, Induced, Ovarian Neoplasms pathology, Peritoneal Neoplasms pathology, Peritoneal Neoplasms therapy, Societies, Medical, Carcinoma, Ovarian Epithelial therapy, Ovarian Neoplasms therapy
Abstract

Adjuvant chemotherapy with carboplatin and paclitaxel is recommended for all high-grade ovarian or Fallopian tube cancers, stage FIGO I-IIA (grade A). After a complete first surgery, it is recommended to deliver 6 cycles of intravenous (grade A) or to propose intraperitoneal (grade B) chemotherapy, to be discussed with patient, according to the benefit/risk ratio. After a complete interval surgery for a FIGO III stage, the hyperthermic intra peritoneal chemotherapy (HIPEC) can be proposed in the same conditions of the OV-HIPEC trial (grade B). In case of tumor residue after surgery or FIGO stage IV, chemotherapy associated with bevacizumab is recommended (grade A). For BRCA mutated patient, Olaparib is recommended (grade B)., (Copyright © 2019 Elsevier Masson SAS. All rights reserved.)

Published
2019
Full Text
View/download PDF

11. [Malignant epithelial ovarian cancer: Role of intra peritoneal chemotherapy and hyperthermic intra peritoneal chemotherapy (HIPEC): Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].

Author

Bakrin N and Gladieff L

Subjects
Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Ovarian Epithelial mortality, Carcinoma, Ovarian Epithelial pathology, Chemotherapy, Adjuvant, Cisplatin administration & dosage, Fallopian Tube Neoplasms drug therapy, Fallopian Tube Neoplasms secondary, Female, France, Humans, Ovarian Neoplasms mortality, Ovarian Neoplasms pathology, Paclitaxel administration & dosage, Peritoneal Neoplasms secondary, Quality of Life, Societies, Medical, Carcinoma, Ovarian Epithelial therapy, Hyperthermia, Induced, Ovarian Neoplasms therapy, Peritoneal Neoplasms drug therapy
Abstract

Intraperitoneal drug delivery in first-line treatment of advanced ovarian cancer have been widely studied. After a complete primary surgery or with residual disease<1cm, intraperitoneal chemotherapy significantly improves disease-free and overall survival (NP1), but with more local and systemic toxicities. Whenever this therapeutic option is under consideration, the ratio efficacy/toxicity must be carefully discussed. Intraperitoneal chemotherapy has to be considered after complete or optimal primary surgery in ovarian, tubal or primitive peritoneal carcinomatosis FIGO IIIC. This treatment must be performed by trained teams and after an assessment of the ratio efficacy/toxicity. In one randomized study, hyperthermic intraperitoneal chemotherapy (HIPEC) using cisplatinum at interval surgery demonstrated an improvement in recurrence free and overall survival compared to surgery alone, in patients initially not resectable and with residual tumor less than 1cm (complete or optimal surgery) (NP1). HIPEC has to be considered after a complete or optimal interval surgery (residu<10mm) in patients with ovarian, tubal or primitive carcinomatosis FIGO IIIC, initially not resectable (Grade B)., (Copyright © 2019. Published by Elsevier Masson SAS.)

Published
2019
Full Text
View/download PDF

12. [HIPEC and ovarian carcinoma: base judgment on evidence].

Author

Bakrin N, Glehen O, and Golfier F

Subjects
Female, Humans, Infusions, Parenteral, Randomized Controlled Trials as Topic, Treatment Outcome, Antineoplastic Agents administration & dosage, Carcinoma drug therapy, Carcinoma surgery, Hyperthermia, Induced, Organoplatinum Compounds administration & dosage, Ovarian Neoplasms drug therapy, Ovarian Neoplasms surgery
Published
2012
Full Text
View/download PDF

13. [Severe gestational hypertriglyceridemia: related complications and management].

Author

Huissoud C, Robert JM, Bakrin N, Rudigoz RC, and Levrat A

Subjects
Acute Kidney Injury etiology, Acute Kidney Injury therapy, Adult, Female, Fetal Death etiology, Fetal Distress etiology, Humans, Pancreatitis complications, Pancreatitis prevention & control, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, Second, Pregnancy Trimester, Third, Hypertriglyceridemia complications, Hypertriglyceridemia therapy, Pancreatitis etiology, Pregnancy Complications therapy
Abstract

We present two cases of severe hypertriglyceridemia (HTG>10g/l) in pregnancy. The first reports the case of a primigravida with mild HTG before conception. Triglycerides (TG) increased thereafter (20.9g/l) during pregnancy causing pancreatitis and in utero fetal death at 24 weeks' gestation (WG). The second deals with the de novo occurrence of a severe HTG (19g/l) diagnosed incidentally at 34 WG and complicated by acute renal failure. Severe HTG in pregnancy threatens maternal and fetal prognosis. We have summarized the curative and preventive management of gravidic HTG.

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results